HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Video All Versions of this Article: 01.wnl.0000234852.43688.bfv1 67/3/480    most recent Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mercimek-Mahmutoglu, S. Articles by Jakobs, C. Search for Related Content PubMed PubMed Citation Articles by Mercimek-Mahmutoglu, S. Articles by Jakobs, C. Related Collections Metabolic disease (inherited) Amino acid All Clinical trials Clinical trials Observational study (Cohort, Case control)

GAMT deficiency

Features, treatment, and outcome in an inborn error of creatine synthesis

From the Division of Biochemical Diseases (S.M.-M., S.S.I.), British Columbia Children’s Hospital, Vancouver, Canada; U.O. di Pediatria Azienda (A.A.), Ospidaliera San Carlo Borromeo, Milan, Italy; Royal Liverpool Children’s Hospital (R.A.), NHS Trust Hospital, Liverpool, England; Unidade de Ciências da Saúde (H.C.A.), Universidade da Madeira, Funchal, Portugal; Laboratory Genetic Metabolic Diseases (M.D.), Academic Medical Centre, Amsterdam, The Netherlands; Pediatric Research enter (R.E.), Dr. von Haunersches Kinderspital, Ludwig-Maximilians-University Munich, Germany; Neuropediatric Department (E.F.A.), Hospital Sant Joan de Déu, Barcelona, Spain; Hospital Pediatrico de Coimbra (P.G.), Portugal; Kinderkrankenhaus Kliniken Stadt Koeln (C.G.), Koeln, Germany; Department of Pediatrics (C.B.I., A.M.), Medical University Vienna, Vienna, Austria; Department of Child Neurology and Psychiatry (V.L.), Universita La Sapienza, Rome, Italy; Zentrum fuer Kinder- und Jungendmedizin (I.M.), Abteilung fuer Neuropaediatrie, Oldenburg, Germany; Swiss Epilepsy Centre (R.A.S.-K.), Zurich, Switzerland; Department of Clinical Chemistry (C.J., G.S.S., N.M.V.), Metabolic Unit and Department of Child Neurology (M.v.d.K.), VU University Medical Center Amsterdam, The Netherlands; AS: Department of Pediatrics I (A.S.), University Children’s Hospital, Heidelberg, Germany; Neurosciences Unit (R.S.), Institute of Child Health, Wolfson Centre, London, UK; Centro Psicopedagógico da Sagrada Família (R.V.), Funchal, Portugal; Unidade de Biologia Clinica (L.V.), Instituto de Genetica Medica Jacinto de Magalhaes, Porto, Portugal; Children’s Hospital (E.W.), Georg-August-University, Goettingen, Germany.

Address correspondence and reprint requests to Dr. Sylvia Stoeckler-Ipsiroglu, Department of Pediatrics, University of British Columbia, Division of Biochemical Diseases, British Columbia Children’s Hospital, 4480 Oak Street, Vancouver, BC V6H 3V4, Canada; e-mail: sstockler{at}cw.bc.ca

Background: Guanidinoactetate methyltransferase (GAMT) deficiency is an autosomal recessive disorder of creatine synthesis. The authors analyzed clinical, biochemical, and molecular findings in 27 patients.

Methods: The authors collected data from questionnaires and literature reports. A score including degree of intellectual disability, epileptic seizures, and movement disorder was developed and used to classify clinical phenotype as severe, moderate, or mild. Score and biochemical data were assessed before and during treatment with oral creatine substitution alone or with additional dietary arginine restriction and ornithine supplementation.

Results: Intellectual disability, epileptic seizures, guanidinoacetate accumulation in body fluids, and deficiency of brain creatine were common in all 27 patients. Twelve patients had severe, 12 patients had moderate, and three patients had mild clinical phenotype. Twenty-one of 27 (78%) patients had severe intellectual disability (estimated IQ 20 to 34). There was no obvious correlation between severity of the clinical phenotype, guanidinoacetate accumulation in body fluids, and GAMT mutations. Treatment resulted in almost normalized cerebral creatine levels, reduced guanidinoacetate accumulation, and in improvement of epilepsy and movement disorder, whereas the degree of intellectual disability remained unchanged.

Conclusion: Guanidinoactetate methyltransferase deficiency should be considered in patients with unexplained intellectual disability, and urinary guanidinoacetate should be determined as an initial diagnostic approach.

Additional material related to this article can be found on the Neurology Web site. Go to www.neurology.org and scroll down the Table of Contents for the August 8 issue to find the title link for this article.

This article was previously published in electronic format as an Expedited E-Pub on www.neurology.org.

Dr. Mercimek-Mahmutoglu was supported by the National Austrian Treasury Research Fund (ÖNB 9802) and by Scientific Hospital Supply, Heilbronn, Germany. Dr. Item was supported by National Austrian Treasury Research Funds (ÖNB 6388, 7676, 9029, 9802).

Disclosure: The authors report no conflicts of interest.

Received March 23, 2005. Accepted in final form March 30, 2006.

This article has been cited by other articles:

				B. Manzi, A. L. Loizzo, G. Giana, and P. Curatolo Autism and Metabolic Diseases J Child Neurol, March 1, 2008; 23(3): 307 - 314. [Abstract] [PDF]

				V. Leuzzi, M. L. Di Sabato, F. Deodato, C. Rizzo, S. Boenzi, C. Carducci, P. Malaspina, C. Liberanome, and C. Dionisi-Vici Vigabatrin improves paroxysmal dystonia in succinic semialdehyde dehydrogenase deficiency Neurology, April 17, 2007; 68(16): 1320 - 1321. [Full Text] [PDF]